177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌有效性和安全性的meta分析

Efficacy and safety of the Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer:A meta-analysis

目的:利用meta分析的方法依据现有的临床证据评价177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的有效性及安全性。方法:通过计算机检索PubMed、Medline、EMBASE、Cochrane图书馆以及CNKI、VIP、CBM、万方数据库从建立至2019年7月有关177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的回顾性研究,由2名研究者按照纳入与排出标准进行文献筛选、资料提取和质量评价,并采用STATA15.1软件进行meta分析。结果:共计纳入12项关于177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的回顾性研究,纳入患者508例。其中经过一周期治疗后出现PSA下降的合并率为69.30%(95%CI,65.40%~73.30%),而经过一周期治疗后PSA下降超过50%的合并率为35.90%(95%CI,31.80%~40.00%)。在12项研究中,均无明显治疗不良反应发生。结论:177Lu-PSMA-617在治疗转移性去势抵抗性前列癌过程中,未有明显的不良反应发生,可以作为一种安全有效的治疗手段。

Objective: To evaluate the clinical efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer(mCRPC). Methods:We searched PubMed, Medline, Embase, Cochrane Library, CNKI, VIP, CBM and Wanfang Database from inception to July 2019 for published retrospective studies on the treatment of mCRPC. We performed literature screening, data extraction and quality evaluation according to the inclusion and exclusion criteria, and conducted a meta-analysis of the data obtained using the STATA15.1 software. Results: A total of 12 studies involving 508 cases of mCRPC were included in this analysis. After the first cycle of treatment, the pooled rate of PSA decline was 69.30%(95% CI: 65.40%-73.30%), and that of >50% PSA decline was 35.90%(95% CI: 31.80%-40.00%). No significant adverse events were reported in any of the studies. Conclusion: The177Lu-PSMA-617 therapy is a safe and effective option for the treatment of metastatic castration-resistant prostate cancer.